Novel Treatment in Age-related Macular Degeneration (Ongoing)

Posted On 2020-11-12 10:59:27



The Series on “Novel Treatment in Age-related Macular Degeneration” is edited by Sayena Jabbehdari, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.

Sayena Jabbehdari, MD MPH
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA

Sayena Jabbehdari is a clinician-scientist in the field of Ophthalmology at the Illinois Eye and Ear Infirmary at University of Illinois at Chicago (UIC). She is the member of American Academy of Ophthalmology (AAO) and the Association for Research in Vision and Ophthalmology (ARVO). She has more than 53 publications in peer reviewed journals and three book chapters in the Cornea book (5th edition), and the Pediatric Retina book. Her research interest is diet modification and antioxidant therapy to reverse aging pathways in the retinal diseases.

The main purpose of this series:
Age-related macular degeneration (AMD or ARMD) is the first blindness cause in Western countries and also the third irreversible disease in the world. AMD is often featured by progressive visual impairment, which seriously affects life qualities of the elderly. Discussion and comparison of novel therapies for age-related macular degeneration could benefit the patients and inspire us the in-depth exploration in the ophthalmology field.

Series outline:

  1. Risuteganib or Integrin Inhibitors and Age-related Macular Degeneration
  2. Statin and Age-related Macular Degeneration
  3. Gene Therapy or Gene Polymorphism in the Age-related Macular Degeneration
  4. Role of Amniotic Membrane in the Age-related Macular Degeneration
  5. Role of Abicipar in the Age-related Macular Degeneration
  6. Reversing Mitochondrial Dysfunction in the Age-related Macular Degeneration
  7. Drug Delivery in the Age-related Macular Degeneration
  8. Brolucizumab or Antibody Fragments AND Age-related Macular Degeneration

Disclosure:
The series “Novel Treatment in Age-related Macular Degeneration” was commissioned by the editorial office, Annals of Eye Science without any sponsorship or funding. Sayena Jabbehdari is serving as the unpaid Guest Editor for the series.